MAGI2 and prostate carcinoma: Some genomic rearrangements of MAGI2 have also been evidenced in melanoma cell lines and prostate cancers leading to in-frame deleted transcript with an unknown biological significance, and to MAGI2 invalidation, respectively [130,131].